

Bo Liang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4115630/publications.pdf>

Version: 2024-02-01

16
papers

399
citations

759055

12
h-index

940416

16
g-index

16
all docs

16
docs citations

16
times ranked

580
citing authors

#	ARTICLE	IF	CITATIONS
1	A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV. <i>Journal of Virology</i> , 2020, 95, .	1.5	12
2	Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates. <i>PLoS ONE</i> , 2020, 15, e0228572.	1.1	13
3	Effects of Alterations to the CX3C Motif and Secreted Form of Human Respiratory Syncytial Virus (RSV) G Protein on Immune Responses to a Parainfluenza Virus Vector Expressing the RSV G Protein. <i>Journal of Virology</i> , 2019, 93, .	1.5	20
4	Murine Pneumonia Virus Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus from an Added Gene Is Highly Attenuated and Immunogenic in Rhesus Macaques. <i>Journal of Virology</i> , 2018, 92, .	1.5	9
5	Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP Administered Intranasally Is Immunogenic in African Green Monkeys. <i>Journal of Virology</i> , 2017, 91, .	1.5	13
6	Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate. <i>Journal of Virology</i> , 2017, 91, .	1.5	30
7	Genetic stability of genome-scale deoptimized RNA virus vaccine candidates under selective pressure. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E386-E395.	3.3	41
8	Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F. <i>Journal of Virology</i> , 2017, 91, .	1.5	15
9	Actin-Related Protein 2 (ARP2) and Virus-Induced Filopodia Facilitate Human Respiratory Syncytial Virus Spread. <i>PLoS Pathogens</i> , 2016, 12, e1006062.	2.1	59
10	Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector. <i>Journal of Virology</i> , 2016, 90, 10022-10038.	1.5	31
11	Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate. <i>Journal of Virology</i> , 2015, 89, 9499-9510.	1.5	58
12	Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine. <i>Journal of Virology</i> , 2015, 89, 10319-10332.	1.5	15
13	Chimeric Bovine/Human Parainfluenza Virus Type 3 Expressing Respiratory Syncytial Virus (RSV) F Glycoprotein: Effect of Insert Position on Expression, Replication, Immunogenicity, Stability, and Protection against RSV Infection. <i>Journal of Virology</i> , 2014, 88, 4237-4250.	1.5	27
14	Stimulation of BK Virus DNA Replication by NFI Family Transcription Factors. <i>Journal of Virology</i> , 2012, 86, 3264-3275.	1.5	27
15	Inhibition of Human BK Polyomavirus Replication by Small Noncoding RNAs. <i>Journal of Virology</i> , 2011, 85, 6930-6940.	1.5	14
16	Restriction of Human Polyomavirus BK Virus DNA Replication in Murine Cells and Extracts. <i>Journal of Virology</i> , 2009, 83, 5708-5717.	1.5	15